TY  - JOUR
AU  - Perez-Fidalgo, J A
AU  - Cortés, A
AU  - Guerra, E
AU  - García, Y
AU  - Iglesias, M
AU  - Bohn Sarmiento, U
AU  - Calvo García, E
AU  - Manso Sánchez, L
AU  - Santaballa, A
AU  - Oaknin, A
AU  - Redondo, A
AU  - Rubio, M J
AU  - González-Martín, A
PY  - 2021
DO  - 10.1016/j.esmoop.2021.100212
UR  - https://hdl.handle.net/10668/25902
T2  - ESMO open
AB  - There is limited evidence for the benefit of olaparib in platinum-resistant ovarian cancer (PROC) patients with BRCA wild-type tumors. This study investigated whether this combination of a DNA-damaging chemotherapy plus olaparib is effective in PROC...
LA  - en
KW  - BRCA wild-type
KW  - PARP inhibitor
KW  - olaparib
KW  - pegylated liposomal doxorubicin
KW  - platinum-resistant recurrent ovarian cancer
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Disease-Free Survival
KW  - Doxorubicin
KW  - Female
KW  - Humans
KW  - Neoplasm Recurrence, Local
KW  - Ovarian Neoplasms
KW  - Phthalazines
KW  - Piperazines
KW  - Polyethylene Glycols
TI  - Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).
TY  - research article
VL  - 6
ER  -